Profile data is unavailable for this security.
About the company
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
- Revenue in USD (TTM)0.00
- Net income in USD-32.28m
- Incorporated2006
- Employees16.00
- LocationSellas Life Sciences Group Inc7 TIMES SQUARE, SUITE 2503NEW YORK 10036United StatesUSA
- Phone+1 (646) 200-5278
- Fax+1 (302) 636-5454
- Websitehttps://www.sellaslifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Armata Pharmaceuticals Inc | 5.47m | -41.36m | 75.62m | 66.00 | -- | -- | -- | 13.83 | -1.24 | -1.24 | 0.1312 | -1.41 | 0.0518 | -- | 1.02 | 82,833.34 | -39.21 | -59.78 | -116.66 | -72.70 | -- | -- | -756.59 | -1,113.72 | -- | -- | 1.90 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Aerovate Therapeutics Inc | 0.00 | -84.61m | 76.79m | 51.00 | -- | 0.954 | -- | -- | -2.99 | -2.99 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -72.99 | -- | -81.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.67m | 76.79m | 50.00 | -- | 0.5957 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -17.78m | 77.64m | 10.00 | -- | 27.76 | -- | -- | -0.8864 | -0.8864 | 0.00 | 0.0807 | 0.00 | -- | -- | 0.00 | -149.60 | -- | -225.38 | -- | -- | -- | -- | -- | -- | -- | 0.0403 | -- | -- | -- | -272.15 | -- | -- | -- |
| Chimerix Inc | 159.00k | -83.59m | 79.14m | 72.00 | -- | 0.5829 | -- | 497.76 | -0.9351 | -0.9351 | 0.0018 | 1.51 | 0.0008 | -- | 1.92 | 2,208.33 | -43.54 | -30.45 | -48.29 | -34.09 | 2.52 | -- | -52,574.84 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| CervoMed Inc | 10.07m | -11.95m | 79.57m | 8.00 | -- | 1.74 | -- | 7.90 | -1.60 | -1.60 | 1.35 | 5.53 | 0.3305 | -- | -- | 1,258,319.00 | -39.22 | -53.67 | -43.28 | -58.89 | -- | -- | -118.68 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -53.26m | 79.63m | 32.00 | -- | 1.77 | -- | -- | -1.25 | -1.25 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -50.27 | -42.72 | -52.16 | -46.06 | -- | -- | -- | -- | -- | -- | 0.249 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Clearside Biomedical Inc | 7.70m | -31.88m | 79.64m | 30.00 | -- | -- | -- | 10.34 | -0.4503 | -0.4503 | 0.1094 | -0.4654 | 0.2423 | -- | 9.23 | 256,766.70 | -100.27 | -63.57 | -122.24 | -81.77 | 97.01 | -- | -413.83 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Adicet Bio Inc | 0.00 | -117.88m | 79.69m | 143.00 | -- | 0.3767 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -32.28m | 79.77m | 16.00 | -- | 5.02 | -- | -- | -0.7113 | -0.7113 | 0.00 | 0.2468 | 0.00 | -- | -- | 0.00 | -186.64 | -111.48 | -527.32 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Renovaro Inc | 0.00 | -115.69m | 79.96m | 25.00 | -- | 0.8096 | -- | -- | -0.9343 | -0.9343 | 0.00 | 0.6223 | 0.00 | -- | -- | 0.00 | -128.97 | -39.86 | -158.19 | -42.11 | -- | -- | -- | -- | -- | -9.65 | 0.0259 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
| MDxHealth SA | 80.74m | -40.80m | 80.19m | 300.00 | -- | -- | -- | 0.9931 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -51.47m | 81.24m | 63.00 | -- | 0.4105 | -- | -- | -0.9998 | -0.9998 | 0.00 | 3.82 | 0.00 | -- | -- | 0.00 | -21.24 | -21.16 | -22.36 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Inotiv Inc | 501.06m | -99.22m | 83.49m | 1.96k | -- | 0.4584 | -- | 0.1666 | -3.84 | -3.84 | 19.44 | 7.00 | 0.615 | 8.12 | 6.83 | 256,297.70 | -12.11 | -23.84 | -19.28 | -29.26 | 24.93 | 29.31 | -19.70 | -33.24 | 0.2279 | -0.6234 | 0.6774 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Allakos Inc | 0.00 | -178.75m | 83.91m | 131.00 | -- | 1.15 | -- | -- | -2.03 | -2.03 | 0.00 | 0.8142 | 0.00 | -- | -- | 0.00 | -87.64 | -42.71 | -97.01 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
Data as of Nov 21 2024. Currency figures normalised to Sellas Life Sciences Group Inc's reporting currency: US Dollar USD
7.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.26m | 3.51% |
| Anson Funds Management LPas of 30 Sep 2024 | 793.84k | 1.23% |
| Geode Capital Management LLCas of 30 Sep 2024 | 605.19k | 0.94% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 419.46k | 0.65% |
| Opus Capital Group LLCas of 30 Sep 2024 | 226.10k | 0.35% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 174.53k | 0.27% |
| Diametric Capital LPas of 30 Sep 2024 | 160.19k | 0.25% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 100.84k | 0.16% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 92.94k | 0.14% |
| Virtu Americas LLCas of 30 Jun 2024 | 63.84k | 0.10% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
